Long-Term Monitoring of Hepatitis B Reactivation in Adults Receiving Immunosuppressive Therapy REANT Study on Safety of Oral Antiviral Treatment in Immunocompromised Patients

What this Trial Is About

Researchers are studying patients with latent Hepatitis B virus HBV infection who require immunosuppressive therapy and antiviral prophylaxis. The study aims to monitor long-term effects on bone, kidney, and metabolic health associated with oral antiviral treatment and other health factors. This multicenter, prospective research hopes to improve understanding of the safety and management of HBV prophylaxis in immunocompromised patients. Participants will include those starting HBV antiviral prophylaxis under immunosuppressive treatment. The study will follow patients for four years, collecting data at multiple time points including baseline, and weeks 6, 12, 24, and 48. Assessments will include bone density scans, kidney function tests, metabolic profiles, and liver evaluations to analyze organ health during antiviral use. Throughout the study, patients will attend scheduled visits for comprehensive monitoring of their bone, kidney, metabolic, and liver status. Data will be recorded in a centralized system to ensure accurate tracking. The main outcomes measured are kidney function, bone health, and metabolic status over the first year, with additional liver assessments. Participation includes regular testing and follow-up to understand long-term effects of antiviral therapy.

HBV Reactivation in Immunocompromised Patients (REANT STUDY)